Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR‑194‑5p and SRY‑box 17 (SOX17) mRNA were detected in breast cancer tissues and cell lines by reverse transcription‑quantitative polymerase chain reaction.
|
30272253 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The over-expression of tumour suppressor genes such as RB and SOX17 and down-regulation of an oncogene such as SOX2 were in accordance to the inhibitory role of miR-340 that causes blockage of breast cancer metastasis which should be further investigated.
|
27229858 |
2017 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SOX17 methylation status in CTCs and ctDNA was comparable and was associated with CK-19 expression but was not reflecting the status of primary tumours in breast cancer.
|
29069768 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ctDNA we observed methylation of: a) CST6, in 5/30(17%) and 10/31(32%), b) BRMS1 in 8/30 (27%) and 8/31 (26%) c) SOX17 in 5/30(17%) and 13/31(42%) early breast cancer patients and patients with verified metastasis respectively.
|
27510924 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that SOX17 expression is a useful prognostic biomarker for breast cancer.
|
25971583 |
2015 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SOX17 promoter was found methylated in 96/134 (71.6%) breast cancer samples, while none of the 31 non-cancerous samples tested was positive (0%).
|
25727515 |
2015 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Overall and disease-free survival (DFS) curves were calculated using Kaplan-Meier analysis, and the differences between curves were analyzed by log-rank tests.The frequency of Sox17 gene methylation was 72.9% (113/155) in breast cancer tissues and 58.1% (90/155) in plasma DNA.
|
25789956 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified networks regulated by known cancer drivers such as GATA3 and FOXA1 (breast cancer), SOX17 and FOXA2 (endometrial cancer), and NFE2L2, SOX2, and TP63 (squamous cell lung cancer).
|
25994056 |
2015 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
There was a significant correlation between SOX17 methylation in cfDNA and CTCs in patients with early breast cancer (P = 0.008), but not in patients with verified metastasis (P = 0.283).
|
23136251 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Restored expression of Sox17 by 5-aza-dC treatment decreased the expression level of beta-catenin in breast cancer cell lines.
|
19301122 |
2010 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells.
|
20040597 |
2010 |